NCT06417801View on ClinicalTrials.gov

Prevalence of Emerging Treatment-induced Mutations in Metastatic ER-positive Breast Cancer.

RecruitingOBSERVATIONAL

Enrollment

70

Participants

Timeline

Start Date

June 17, 2024

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2025

Conditions

Metastatic Breast Cancer

Trial Locations (1)

04513-020

RECRUITING

Research Site, São Paulo

Sponsors

Lead Sponsor

All Listed Sponsors

lead

AstraZeneca

INDUSTRY